---
title: "AngioDynamics posts record Q4 and fiscal 2026 results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292736670.md"
description: "AngioDynamics reported record Q4 and fiscal 2026 results, with pro forma net sales rising 8.0% to $86.6 million and 9.4% for the year to $320.2 million. Med Tech revenue grew significantly, driving gross margins above 54%. While GAAP losses persisted, adjusted EBITDA improved to $13.2 million for the full year, ending with $53.9 million in cash. The company advanced clinical initiatives and secured Medicare coverage for NanoKnife."
datetime: "2026-07-15T08:08:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292736670.md)
  - [en](https://longbridge.com/en/news/292736670.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292736670.md)
generator: "portal-rs"
---

# AngioDynamics posts record Q4 and fiscal 2026 results

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

AngioDynamics ( (ANGO) ) has shared an announcement.

AngioDynamics reported record financial results for its fiscal fourth quarter and full year ended May 31, 2026, highlighting a seventh consecutive quarter of double-digit Med Tech growth and positive adjusted EBITDA. Pro forma net sales rose 8.0% in the quarter to $86.6 million and 9.4% for the year to $320.2 million, with Med Tech revenue up 16.7% in the quarter and 18.4% for the year, driving gross margins above 54% despite tariff headwinds.

The company remained loss-making on a GAAP basis, posting a quarterly loss per share of $0.27 and a full-year loss per share of $0.88, but narrowed its adjusted loss and lifted adjusted EBITDA to $3.3 million in the quarter and $13.2 million for the year, ending fiscal 2026 with $53.9 million in cash. Operationally, AngioDynamics advanced key clinical and regulatory initiatives for NanoKnife and its mechanical thrombectomy platforms, secured pivotal Medicare coverage for NanoKnife in prostate and liver cancer, and continued shifting its revenue mix toward higher-growth, higher-margin Med Tech offerings, bolstering its positioning in large, fast-growing cardiology and interventional oncology markets.

The most recent analyst rating on (ANGO) stock is a Buy  
 with a $24.00 price target.  
 To see the full list of analyst forecasts on AngioDynamics stock,  
 see the ANGO Stock Forecast page. 

**Spark’s Take on ANGO Stock**

According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.

The score reflects a stabilizing but still developing story: financial performance is held back by persistent losses and inconsistent free cash flow, partially offset by a low-leverage balance sheet and improved cash generation. Technical indicators are moderately positive with price above key moving averages. The latest earnings call adds support via improving margins/EBITDA and continued growth guidance, while valuation remains constrained by unprofitability and no dividend support.

To see Spark’s full report on ANGO stock,  
 click here. 

**More about AngioDynamics**

AngioDynamics, Inc., based in Latham, N.Y., is a medical technology company specializing in devices that restore healthy blood flow in the vascular system, expand cancer treatment options and improve patient quality of life. Its Med Tech portfolio includes the Auryon peripheral atherectomy platform, thrombus management systems AlphaVac and AngioVac, and the NanoKnife irreversible electroporation platform, complemented by a broader Med Device product range targeting global cardiology and interventional oncology markets.

**Average Trading Volume:** 367,266

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $527.8M

Find detailed analytics on ANGO stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [ANGO.US](https://longbridge.com/en/quote/ANGO.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)

## Related News & Research

- [AngioDynamics (NASDAQ:ANGO) Share Price Crosses Above 200 Day Moving Average   - Should You Sell?](https://longbridge.com/en/news/296303606.md)
- [ANGO: Med Tech growth and margin expansion drove profitability and a strong, debt-free balance sheet](https://longbridge.com/en/news/292604430.md)
- [Monarch Alternative Capital sells eight seniors housing properties in portfolio exit](https://longbridge.com/en/news/296240718.md)
- [Asker Healthcare Group buys Baltic medtech distributor Ambercell Solutions](https://longbridge.com/en/news/296306272.md)
- [11:19 ETEon Appoints Matthew Lungren, MD, MPH, to Board of Directors](https://longbridge.com/en/news/296375443.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**